Harvard Bioscience (HBIO) Return on Capital Employed (2011 - 2026)
Harvard Bioscience (HBIO) posted quarterly Return on Capital Employed of 0.16% for Q1 2026, up 11240.0% year-over-year from N/an in Q1 2025, and up 99.82% quarter-over-quarter from 85.12% in Q4 2025.
Harvard Bioscience (HBIO) Return on Capital Employed (2011 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Return on Capital Employed for 16 consecutive years, with 0.16% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 11240.0% year-over-year to 0.16%; the TTM figure through Mar 2026 stood at 0.16% (up 11240.0% YoY), while the FY2025 annual figure was 59.68%, down 5162.0% from the prior year.
- Return on Capital Employed improved to 0.16% in Q1 2026 per HBIO's latest filing, from 85.12% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1.69% in Q4 2023 and bottomed at 211.56% in Q2 2025.
- Historically, Return on Capital Employed has averaged 37.9% across 5 years, with a median of 3.68% in 2022.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 20695 bps — and 2026, when it soared 11240 bps.
- Harvard Bioscience's Return on Capital Employed stood at 5.64% in 2022, then soared by 130 bps to 1.69% in 2023, then slumped by 596 bps to 8.4% in 2024, then sank by 914 bps to 85.12% in 2025, then soared by 100 bps to 0.16% in 2026.
- Business Quant data shows HBIO's Return on Capital Employed at 0.16% in Q1 2026, 85.12% in Q4 2025, and 204.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 18.58% |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 6.00% |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 28.11% |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 25.22% |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 5.57% |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 19.71% |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 19.76% |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 4.68% |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 3.28% |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn | -0.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.47% |
| Mar 31, 2026 | -0.16% |
| Dec 31, 2025 | -85.12% |
| Sep 30, 2025 | -204.00% |
| Jun 30, 2025 | -211.56% |
| Mar 31, 2025 | -112.56% |
| Dec 31, 2024 | -8.40% |
| Sep 30, 2024 | -5.53% |
| Jun 30, 2024 | -4.61% |
| Mar 31, 2024 | -1.95% |
| Dec 31, 2023 | 1.69% |
| Sep 30, 2023 | 0.99% |
| Jun 30, 2023 | -1.38% |
| Mar 31, 2023 | 1.25% |
| Dec 31, 2022 | -5.64% |
| Sep 30, 2022 | -3.68% |
| Jun 30, 2022 | -0.35% |
| Mar 31, 2022 | -3.31% |
| Dec 31, 2021 | 1.56% |
| Sep 30, 2021 | 2.39% |